[HTML][HTML] Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell …
KD Courtney, JR Infante, ET Lam… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.gov
Purpose The von Hippel-Lindau tumor suppressor is inactivated in the majority of clear cell
renal cell carcinomas (ccRCCs), leading to inappropriate stabilization of hypoxia-inducible
factor-2α (HIF-2α). PT2385 is a first-in-class HIF-2α antagonist. Objectives of this first-in-
human study were to characterize the safety, pharmacokinetics, pharmacodynamics, and
efficacy, and to identify the recommended phase II dose (RP2D) of PT2385.
renal cell carcinomas (ccRCCs), leading to inappropriate stabilization of hypoxia-inducible
factor-2α (HIF-2α). PT2385 is a first-in-class HIF-2α antagonist. Objectives of this first-in-
human study were to characterize the safety, pharmacokinetics, pharmacodynamics, and
efficacy, and to identify the recommended phase II dose (RP2D) of PT2385.
Abstract
Purpose
The von Hippel-Lindau tumor suppressor is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to inappropriate stabilization of hypoxia-inducible factor-2α (HIF-2α). PT2385 is a first-in-class HIF-2α antagonist. Objectives of this first-in-human study were to characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to identify the recommended phase II dose (RP2D) of PT2385.
ncbi.nlm.nih.gov